RBC sees HCA stock upside from pending Florida Medicaid program

RBC estimates a pending Florida Medicaid state-directed payment program could add $270 million of EBITDA to HCA (not included in current guidance), while CMS approval of Georgia’s $1.9 billion program is expected to add roughly $83 million of EBITDA. Nevada supplemental programs are estimated to provide Universal Health Services with $296 million net reimbursement in 2026 (and $30 million related to 2025); UHS reported Q4 adjusted EPS of $5.88 (in line) and revenue of $4.49B vs $4.51B expected, with adjusted EBITDA $679M (90bps below consensus) but FY26 adjusted EBITDA guidance ~1% above consensus. TD Cowen reiterated a Buy on UHS with a $245 price target; RBC notes approvals could provide upside to consensus and move individual hospital stocks on confirmation.

Analysis

State-directed supplemental Medicaid payments are functionally an earnings-style catalyst with binary/regulatory gating rather than a slow organic demand improvement. That structure creates sharp re-rating potential on approval but also concentrates downside into discrete policy and audit risk windows; market moves will therefore compress into the days/weeks around CMS/state actions rather than drift evenly over quarters.

Second-order winners extend beyond the hospitals themselves: improved near-term cash flow lowers short-term working capital needs and can accelerate share repurchases, debt paydowns, or M&A optionality—actions that tend to hit equity value faster than operational margin improvements. Conversely, payers and smaller independent hospitals without such state program access may face tighter contracting leverage and widening funding dispersion across the sub-sector, amplifying selection effects in earnings beats/misses.

Key risks that can reverse the trade are political/back-end adjustments, CMS interpretive changes, or state budget stress that converts supplemental payments into one-time true-ups or clawbacks; these are highest-probability within 0–12 months post-approval. Watch liquidity and positioning: the market will price the binary into option skew and implied vols ahead of decisions, so trade execution and protection sizing matter as much as directional conviction.

Key Decisions for Investors

• Tactical long HCA equity (size 2–4% of active equity sleeve) into the next CMS/state decision window (1–3 months). Protect with a cheap hedge: buy 3-month OTM puts sized to cap downside to ~8–10% of position value. R/R: asymmetric — limited cost of insurance vs full capture of re-rating if approved.
• Relative-value options pair: buy a 6-month HCA call spread (near-money long, sell higher strike) and sell a same-dated UHS call spread to fund ~50–75% of the premium. This expresses a view that HCA’s re-rating > UHS’s re-rating; max loss is the net premium, target 2x–4x premium if approvals drive outsized HCA upside.
• Event-arbitrage tranche: build a sized position staggered across expiries (one short-dated trade into the decision, one longer 6–12 month trade to capture residual re-rate). Use shorter-dated calls ahead of the event and longer-dated equity or LEAPS after the first approval to roll into persistent upside; this reduces front-loaded vega exposure while retaining upside.
• Tail hedge / portfolio defense: if running a healthcare overweight, buy healthcare index or large-cap hospital sector put protection (1–3 month tenors) around key regulatory calendar dates to guard against a sector-wide policy reversal or broad risk-off that would knock down correlated beneficiaries.